Systemic Right Ventricle
7
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
Systemic Right Ventricle Long-term Outcome
Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
Percutaneous Edge To Edge Repair for the Treatment of Severe Tricuspid Valve Regurgitation in High-surgical Risk Patients With Systemic Right Ventricle : a Multicentric French Cohort (PETER-TRESRIV)
Adaptation of Alveolar-capillary Diffusion at Effort of Subjects Suffering From Complex Congenital Heart Disease